Skip to main content
. 2017 Dec 15;8(70):115315–115325. doi: 10.18632/oncotarget.23258

Figure 3. The effect of gemcitabine on ISRE promoter.

Figure 3

HeLa cells were transfected with plasmid encoding ISRE-luciferase and then treated with various concentrations of gemcitabine or IFN-α. At 8 or 24 hours after compound treatment cells were assayed for the firefly luciferase activity. (A) Gemcitabine (8h), (B) IFN-α (8h), (C) Gemcitabine (24h), and (D) IFN-α (24h). The relative luciferase activities in percentage were calculated by setting the value from DMSO-treated cells as 100%. The average and standard deviation were obtained from three independent experiments.